Pfizer termina alianza con Sangamo en terapia génica para la hemofilia al borde de la presentación ante la FDA.
Pfizer’s partnership with Sangamo Therapeutics produced a gene therapy for hemophilia A that reached discussions with the FDA for a regulatory submission. That’s as far as the alliance will go. Pfizer is terminating the seven-year-old pact, a move that comes before the pharmaceutical giant must pay costly milestone payments for a product with uncertain commercial … Leer más
